Stock 1801 INNOVENT BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:20 26/04/2024 BST 		5-day change 1st Jan Change
39.15 HKD +1.56% Intraday chart for Innovent Biologics, Inc. +17.92% -8.42%
04-17 Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer CI
04-02 Hutchmed endometrial cancer treatment application accepted for review AN

Business Summary

Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.

Number of employees: 4,872

Sales per Business

HKD in Million2021Weight2022Weight Delta
Pharmaceutical Products
100.0 %
5,146 100.0 % 5,299 100.0 % +2.97%

Sales per region

HKD in Million2021Weight2022Weight Delta
China
90.7 %
4,782 92.9 % 4,806 90.7 % +0.50%
United States
9.0 %
315 6.1 % 478 9.0 % +51.58%
Indonesia
0.3 %
8 0.2 % 15 0.3 % +87.12%

Managers

Managers TitleAgeSince
De Chao Yu CEO
 Chief Executive Officer 61 27/04/11
Fei You DFI
 Director of Finance/CFO 45 02-04
Yong-Jun Liu PSD
 President - 14/10/20
Ghang Shou Gao CTO
 Chief Tech/Sci/R&D Officer - -
Qin Wei Zhou COO
 Chief Operating Officer 61 15/06/16
Hao Xi Ede BRD
 Director/Board Member 65 04/06/17
Vivian Zhang HRO
 Human Resources Officer - 29/02/12
Blake Salisbury PRN
 Corporate Officer/Principal - 29/02/16
Yan Ju Wang SEC
 Corporate Secretary 36 30/09/15
Lok Yee Chan SEC
 Corporate Secretary 35 03/06/18

Members of the board

Members of the board TitleAgeSince
Gary Zieziula BRD
 Director/Board Member 69 30/05/22
Charles Cooney BRD
 Director/Board Member 80 17/10/15
De Chao Yu CEO
 Chief Executive Officer 61 27/04/11
I Yin Hsu BRD
 Director/Board Member 50 17/10/18
Hao Xi Ede BRD
 Director/Board Member 65 04/06/17
Kai Xian Chen BRD
 Director/Board Member 79 17/10/18

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,622,682,897 1,509,307,058 ( 93.01 %) 0 93.01 %

Shareholders

NameEquities%Valuation
Temasek Holdings Pte Ltd. (Investment Management)
8.508 %
138,042,850 8.508 % 665 M $
De Chao Yu
6.733 %
109,245,165 6.733 % 526 M $
LAV Management Co., Ltd.
4.748 %
77,036,540 4.748 % 371 M $
Capital International, Inc.
1.354 %
21,969,717 1.354 % 106 M $
GF Fund Management Co., Ltd.
1.212 %
19,662,655 1.212 % 95 M $
Bosera Asset Management Co., Ltd.
0.7213 %
11,704,500 0.7213 % 56 M $
Yu De Chao Family
0.5547 %
9,000,000 0.5547 % 43 M $
Penghua Fund Management Co., Ltd.
0.4382 %
7,109,500 0.4382 % 34 M $
Bank of China Investment Management Co., Ltd.
0.3383 %
5,488,500 0.3383 % 26 M $
China Southern Asset Management Co., Ltd.
0.3066 %
4,974,500 0.3066 % 24 M $

Company contact information

Innovent Biologics, Inc.

168 Dongping Street Suzhou Industrial Park

215123, Suzhou

+86 512 6956 6088

http://www.innoventbio.com
address Innovent Biologics, Inc.(1801)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Innovent Biologics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
36.24 CNY
Average target price
51.18 CNY
Spread / Average Target
+41.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 8.12B
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 1801 Stock
  4. Company Innovent Biologics, Inc.